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Abstract
Introduction: Unintentional medication ingestions by young children lead to nearly 60,000 
emergency department (ED) visits annually; 15% involve oral liquid medications. Safety 
packaging improvements have been shown to limit liquid medication ingestions. Estimated rates 
of ED visits for pediatric ingestions by product were calculated to help target interventions.
Methods: Frequencies and rates of ED visits for unintentional pediatric ingestions were 
estimated using adverse event data from the National Electronic Injury Surveillance System–
Cooperative Adverse Drug Event Surveillance project and retail sales/pharmacy dispensing data 
from Information Resources, Inc. and QuintilesIMS (collected 2012–2015; analyzed 2017). Rates 
of ED visits for ingestions of over-the-counter (OTC) liquid medications were compared with 
those for prescription solid medications.
Results: Based on 568 cases, an estimated 6,427 ED visits (95% confidence interval: 4,907–
7,948) were made annually after a child <6 years accessed one of the four most commonly 
implicated OTC liquid medications without caregiver oversight. Nearly two-thirds (63.8%) of 
these visits were made by children aged ≤2 years and 9.0% resulted in hospitalization. 
Acetaminophen was the most commonly implicated OTC liquid medication (2,515 estimated ED 
visits annually). Rates of ED visits for liquid diphenhydramine and acetaminophen ingestions (8.1 
and 7.4 ED visits per 100,000 bottles sold) were higher than rates for other common OTC liquids 
and comparable to high rate prescription solid medications (clonidine and buprenorphine/naloxone 
[11.1 and 10.5 ED visits per 100,000 dispensed prescriptions]).
Conclusions: Product-specific rates of ED visits for unintentional ingestions can help prioritize 
preventive interventions, such as enhancing safety packaging with flow restrictors.
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Child-resistant (CR) packaging has contributed to significant declines in pediatric deaths 
from medication ingestions.1 However, unintentional medication ingestions by children aged 
<6 years continue to lead to approximately 450,000 poison center calls and 60,000 
emergency department (ED) visits each year in the United States.2,3 Oral liquid medications 
are involved in approximately 15% of ED visits for pediatric medication ingestions,2 and 
although rare, life-threatening ingestions of over-the-counter (OTC) and prescription liquid 
products continue to occur.3, 4 Because the rate of these ingestions relative to units of 
medication sold has not been previously assessed, rates of ED visits for unintentional 
ingestions of common oral liquid medications were calculated and compared to rates for 
commonly ingested solid medications.
METHODS
The numbers of ED visits for unintentional pediatric medication ingestions were estimated 
using data from the National Electronic Injury Surveillance System-Cooperative Adverse 
Drug Event Surveillance (NEISS-CADES) project, a stratified probability sample of 
hospitals in the U.S and its territories with at least 6 beds and 24-hour EDs.5, 6 Trained 
abstractors at the 60 participating hospitals review all ED medical records to identify and 
record clinician-diagnosed adverse drug events, including pediatric medication ingestions.
Cases included ED visits from January 1, 2012 through December 31, 2015 in which a child 
aged <6 years ingested or was suspected of ingesting acetaminophen, diphenhydramine, 
ibuprofen, or cough and cold medicines (CCMs), as previous analyses found that over 75% 
of ED visits for unintentional ingestions of liquid medications involved one of these 
medications.2 Dosage form, prescription status, and intended age group for each product, 
were categorized by a study pharmacist based on case narratives, drug databases, and 
manufacturer websites.7, 8 The four prescription solid medications most commonly 
implicated in ED visits for unintentional ingestions were identified for comparison.
National estimates of OTC liquid medication bottles sold were obtained from Information 
Resources, Inc. (IRI). IRI data include complete point-of-sale data for mass merchandise, 
club, dollar, and military stores and estimated sales for drug and food stores (based on 92% 
and 75% coverage, respectively). National estimates of prescriptions dispensed from 
outpatient retail pharmacies were obtained from QuintilesIMS National Prescription Audit. 
QuintilesIMS uses proprietary methods to estimate dispensed prescriptions based on data 
from nearly 48,000 retail pharmacies (representing approximately 80% of prescriptions from 
drug, food, and mass merchandise stores).
Annual national estimates of ED visits and corresponding 95% confidence intervals (CIs) 
were calculated using the SURVEYMEANS procedure in SAS, version 9.3 (SAS Institute) 
to account for sample weights and complex sample design.9 Rates were calculated by 
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dividing the estimated number of ED visits (NEISS-CADES) by the estimated numbers of 
bottles sold or prescriptions dispensed.
RESULTS
Based on 568 cases, an estimated 6,427 ED visits (95% CI: 4,907–7,948) were made 
annually for unintentional ingestions of one of the four most commonly implicated OTC 
liquid medications from 2012–2015 (Table 1). During this time, 4,489 estimated visits (95% 
CI: 3,307–5,670) were made for unintentional ingestions of one of the four most commonly 
implicated prescription solid medications. The top four OTC liquid medications were 
implicated in an estimated 10.7% (95% CI: 9.3%−12.1%) of all ED visits for unintentional 
medication ingestions and the top four prescription solid medications were implicated in 
7.5% (95% CI: 6.2%−8.8%).
Acetaminophen was the most commonly implicated OTC liquid medication in ED visits for 
pediatric ingestions, accounting for an estimated 2,515 ED visits annually (Table 2). While 
nearly all ED visits for ingestions of OTC liquid acetaminophen (98.7%; 95% CI: 96.2%
−100.0%), diphenhydramine (98.1%; 95% CI: 95.2%−100.0%), and ibuprofen (100.0%) 
involved pediatric formulations; fewer visits attributed to CCMs definitively involved 
pediatric formations (58.5%; 95% CI: 41.2%−75.9%). There were an additional 920 annual 
ED visits (95% CI: 392–1,448) for ingestion of the top four OTC medications for which the 
dosage form was not specified, but even if all were oral liquid products, there were no 
significant changes in the proportion of estimated visits by patient or case characteristics, or 
by implicated medication (Appendix).
Estimated rates of ED visits for liquid diphenhydramine and acetaminophen ingestions (8.1 
and 7.4 ED visits per 100,000 bottles sold) were significantly higher than rates of ED visits 
for ibuprofen and CCM ingestions (Table 2). The rate of ED visits involving pediatric CCMs 
was more than 4-times the rate involving family or adult CCMs or those for which the age 
group was not specified (2.3 vs. 0.5 ED visits per 100,000 bottles sold). Estimated rates of 
ED visits for pediatric ingestions per bottle sold for diphenhydramine and acetaminophen 
were comparable to the rates per prescription dispensed for clonidine and buprenorphine/
naloxone (11.1 and 10.5 ED visits per 100,000 dispensed prescriptions).
DISCUSSION
One reason unintentional ingestions of liquid medications by young children persist despite 
CR packaging is that most CR packaging in the U.S. uses safety closures/caps on multidose 
bottles which requires that parents/caregivers immediately and fully re-secure CR closures 
after every use. To mitigate this limitation, restricted delivery systems such as “flow 
restrictors,” adapters that narrow bottle openings or create re-closable seals, have been added 
to some liquid medications.10–13 These devices add an automatic, passive safety barrier and 
were voluntarily added to infants’ acetaminophen in 2011 and subsequently added to some 
children’s acetaminophen products.13 Based on calls to poison centers, when bottles had 
flow restrictors, pediatric ingestions of liquid acetaminophen were found to be significantly 
less likely to involve clinically significant doses.14, 15
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A 2015 U.S. Food and Drug Administration (FDA) voluntary guidance recommends 
adoption of container features, such as flow restrictors, to reduce the incidence and 
magnitude of pediatric ingestions on all pediatric OTC liquid products containing 
acetaminophen.16 Recommendations to use such restricted delivery systems for other 
medicines is currently under consideration by FDA17 and recommended by other 
professional and standards organizations.12, 18 An ASTM Standard Test Method to help 
manufacturers assess optimal flow restrictors for specific products is under development.19
Which products might be candidates for enhanced safety features? ED visits for pediatric 
ingestion of liquid diphenhydramine products and liquid acetaminophen products occurred 
at 3-times the estimated rate compared with ibuprofen and pediatric CCM products and at 
rates comparable to the concerning prescription solid medications clonidine and 
buprenorphine/naloxone.20, 21 While voluntary FDA guidelines already recommend such 
features for pediatric liquid acetaminophen-containing products, acute toxicity of 
diphenhydramine may be greater than acetaminophen after ingestion of comparable 
volumes. Based on current guidelines, a child aged <5 years would likely be referred for 
emergency evaluation only after ingesting a full 120 mL bottle of children’s acetaminophen 
but after just one-half of a 120 mL bottle of children’s diphenhydramine.22, 23 Flow 
restrictors could be expected to prevent ingestion of such volumes, and need for subsequent 
ED visits, as in a randomized trial, only 6% of preschool-aged children were able to empty 
bottles with flow restrictors and no children aged <3½ years removed even 5 mL.24
Although CCMs and prescription liquid medications2 lead to fewer ED visits than other 
OTC products, ingestion of small volumes of certain products (e.g., liquid opioids) may lead 
to significant harm, including death.25 Further investigation of such products for improved 
safety packaging may be justified based on severity of harm rather than frequency of ED 
visits. Additionally, improvements in safety packaging should be combined with reminding 
parents/caregivers to store medications up and away and out of children’s reach and sight.
26, 27
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